Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)


Section Navigation
			
			CDC Home








Latent Tuberculosis Infection Resources						Print
													Updated September 5, 2023
																	Related Pages
					LTBI Resource Hub BannerOn This Page
			Resources for ProvidersResources for PatientsLTBI Reporting Laws, by StateGraphics, Web Buttons, Infographics
		
The online latent TB infection (LTBI) resource hub is a one-stop shop for resources related to:
Education and training
Guidelines
Testing and diagnosis
Infection control and prevention
TreatmentTo order free latent TB infection resources, visit CDC-INFO on Demand.Featured ResourcesStop TB PosterNewThink. Test. Treat TB campaignLatent TB Infection: A Guide for Primary Health Care ProvidersResources for Providers
Open All Close All
Screening and Testing GuidanceAdvisory Council for the Elimination of Tuberculosis (ACET): Roadmap for Advancing TB Elimination in the United States through Scale up of Testing and Treatment of Latent TB Infection [PDF – 1 MB] *(published in ACET Minutes of the Meeting June 16, 2020, Addendum 1, pages 40-51 [PDF – 612KB])*
This statement from ACET updates the strategy to eliminate TB in the United States. The report provides new recommendations to prevent TB, specifically through focus on identifying individuals at risk and testing and treating latent TB infection.Doctor checking patient
USPSTF Latent Tuberculosis Infection: Screening Recommendation
The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms.Screening for Latent Tuberculosis Infection in Adults: US Preventive Services Task Force Recommendation Statementtbbloodtest.jpgTB skin test kit
Interferon-Gamma Release Assays (IGRAs) – Blood Tests for TB InfectionInterferon-Gamma Release Assays (IGRAs) are whole-blood tests that can aid in diagnosing Mycobacterium tuberculosis infection.
Targeted Tuberculosis Testing and Interpreting Tuberculin Skin Test ResultsCDC and USPSTF recommend testing populations that are at increased risk for TB infection. Health care providers should consider several criteria when classifying positive TST reactions.Treatment GuidanceGuidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020
These updated 2020 LTBI treatment guidelines include the NTCA- and CDC-recommended treatment regimens that comprise three preferred rifamycin-based regimens and two alternative monotherapy regimens with daily isoniazid.Latent TB Infection Treatment Regimens – Treatment Table
Latent TB Infection Treatment – FAQ for Clinicians
Latent TB Infection Treatment – FAQ for Pharmacists
**MMWR*/Medscape free CE credit on the updated 2020 latent TB infection treatment guidelines.
Registration may be required.*Update on Recommendations for Use of Once-weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium Tuberculosis InfectionCDC continues to recommend 3HP for treatment of LTBI in adults and now recommends use of 3HP 1) in persons with LTBI aged 2–17 years; 2) in persons with LTBI who have HIV infection, including acquired immunodeficiency syndrome (AIDS), and are taking antiretroviral medications with acceptable drug-drug interactions with rifapentine; and 3) by DOT or self-administered therapy (SAT) in persons aged ≥2 years.The 12-Dose Regimen for Latent TB Infection Treatment: Fact Sheet for Clinicians
Frequently Asked Questions on the 12-dose regimen for Latent TB Infection for Providers
Frequently Asked Questions on the 12-dose regimen for Latent TB Infection for Pharmacists
CDC Medscape Commentary: Latent TB Infection Updated Treatment RecommendationsTreatment Options of Latent Tuberculosis InfectionAvailable fact sheets on TB treatment include:Information on Treatment for Latent TB Infection
12-Dose Regimen for Latent TB Infection Treatment: Fact Sheet for Clinicians
Treatment of Latent Tuberculosis Infection: Maximizing AdherenceGuidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV
These guidelines are intended for clinicians, other health care providers, patients with HIV, and policy makers in the United States.Provider Education Resources•	Latent TB Infection Testing and Treatment: Summary of US Recommendations
Latent TB Infection Testing and Treatment: Summary of U.S. Recommendations
This summary includes information on testing for TB infection, recommended test for TB infection, and recommended treatment regimens for latent TB infection.
Latent Tuberculosis Infection: A Guide for Primary Health Care ProvidersThe guide includes latent TB infection diagnosis and treatment information, sample documentation forms, and additional resources.
Targeted Tuberculosis (TB) Testing and Treatment of Latent TB Infection (slide set)The slide set provides an overview of the current recommendations for the testing and treatment of latent tuberculosis. The target audience for this slide set is primary health care providers.
CDC Messages and Resources
This information may be helpful in communication activities to inform and educate partners, stakeholders, and media about the importance of expanded latent TB infection testing and treatment in eliminating TB in the United States.Resources for PatientsScreening and Testing InformationTesting for TuberculosisThis fact sheet provides information about the two kinds of tests that are used to determine if a person has been infected with TB bacteria: the tuberculin skin test and TB blood tests.
Tuberculin Skin Testing
The Mantoux tuberculin skin test is one method of determining whether a person is infected with Mycobacterium tuberculosis.Treatment InformationInformation and tools for patients on latent TB treatment.
12-Dose Regimen for Latent TB Infection
English
Chinese
Haitian Creole
Marshallese
Spanish
Tagalog
Vietnamese12-Dose Regimen for Latent TB Infection-Medication Tracker and Symptom Checklist
English
Chinese
Haitian Creole
Marshallese
Spanish
Tagalog
Vietnamese4 Months Daily Rifampin Schedule for Latent Tuberculosis (TB) Infection
English
Spanish
3 Months of Daily Isoniazid plus Rifampin (3HR)These fact sheets will give an overview of regimens for latent TB infection and provide resources for patients.
Isoniazid-specific regimen
Rifampin-specific regimen
What You Need to Know About Your Medicine for Latent Tuberculosis (TB) Infection – Isoniazid and RifapentinePatient Education MaterialsQuestions and Answers About Tuberculosis cover
Questions and Answers about TuberculosisQuestions and Answers About Tuberculosis (TB) provides information on the diagnosis and treatment of TB infection and TB disease.English
Spanish
Tagalog
VietnameseSlide Set—Introduction to TuberculosisThis slide set provides a basic overview of TB using plain language and visual aids.Kelcie’s Story of LTBI Testing and TreatmentLike many people, Kelcie wasn’t familiar with latent TB infection and wasn’t sure what she should do about it.Low Resolution Video
5 Things to Know about TB
This video highlights the continuing problem of tuberculosis (TB) in the United States.LTBI Reporting Laws, by StateAll 50 states and the District of Columbia require that cases of  TB disease be reported to local or state health authorities and the CDC; however, reporting latent TB infections to CDC is optional. Some states and localities have developed legal reporting requirements for latent TB infection as a tool to prevent TB disease.
CDC’s Office of Public Health Law Services completed a legal epidemiology assessment of statutes and regulations associated with latent TB infection reporting across 50 states and the District of Columbia. The map and table below provide a summary of findings as of April, 2021.Map of LTBI Reporting Laws, by StateLTBI-Law-Project-map
This map is an Equal-Area Cartogram. The area of each state has been modified so that geographic patterns in the data are easier to identify. In traditional maps of the United States, small states are visually overpowered by large states. An Equal-Area Cartogram may appear distorted because states must be separated to accommodate their new sizes.Summary Table of LTBI Reporting Laws, by StateSummary Table of Latent Tuberculosis Infection (LTBI) Reporting Laws, by State, as of April 2021
State
Does state law expressly require LTBI to be reported?
Who is required to report?
What types of cases must be reported?
CitationsAlabama
NoAlaska
NoArizona
Yes
Healthcare providers or facilities
Other: Administrator of correctional facility; local health agency
Cases in children five years old or younger (positive screening test results)
Ariz. Admin. Code § 9-6-202 & Table 2.1;
Ariz. Admin. Code § 9-6-206 & Table 2.4Arkansas
NoCalifornia
Yes
Laboratories
Lab confirmed
Cal. Code Regs. tit. 17, § 2505Colorado
Yes
Healthcare providers or facilities
Laboratories
Positive interferon-gamma release assay (IGRA) tests for workers in a healthcare, correctional, or detention facility if the worker had prolonged contact with an infectious TB case
Lab confirmed
6 Colo. Code Regs. § 1009-1 Appendix A;
6 Colo. Code Regs. § 1009-1:4Connecticut
NoDelaware
NoFlorida
NoGeorgia
Yes
Healthcare providers or facilities
Laboratories
Cases in children five years old or younger
Ga. Comp. R. & Regs. 511-2-1-.02;
Georgia DPH Notifiable Disease Condition Reporting (December 2020)Hawaii
NoIdaho
NoIllinois
NoIndiana
Yes
Healthcare providers or facilities
Laboratories
Healthcare providers or facilities: all cases
Laboratories: positive interferon-gamma release assay (IGRA) tests only
410 Ind. Admin. Code 1-2.5-75;
410 Ind. Admin. Code 1-2.5-76;
410 Ind. Admin. Code 1-2.5-111Iowa
NoKansas
Yes
Healthcare providers or facilities
Other:  Adult care home administrator; licensed social worker; teacher or school administrator
Lab confirmed
Kan. Stat. Ann. § 65-116;
Kan. Admin. Regs § 28-1-2Kentucky
NoLouisiana
NoMaine
NoMaryland
Yes
Healthcare providers or facilities
Laboratories
Other: Teacher at public, private, or parochial schools; child care provider at any child care facility; the master or person in charge of a vessel or aircraft within the territory of the State; an owner or operator of a food establishment
All cases
Md. Code Regs. 10.06.01.03;
Md. Code Regs. 10.06.01.04;Massachusetts
Yes
Healthcare providers or facilities
Laboratories
Other: Board of health or administrator of a city, state, or private institution
All cases
105 Mass. Code Regs. 300.170;
105 Mass. Code Regs. 300.180;
105 Mass. Code Regs.
300.200Michigan
NoMinnesota
NoMississippi
Yes
Healthcare providers or facilities
Laboratories
Other: Pathologist; medical examiner; coroner; veterinarian
All cases
15 Miss. Admin. Code Pt. 2, Subpt. 11, App. A;
15 Miss. Admin. Code Pt. 2, Subpt. 11, R. 1.1Missouri
Yes
Healthcare providers or facilities
Laboratories
All cases
Mo. Code Regs. Ann. Tit. 19, § 20 -20.020;
Mo. Code Regs. Ann. Tit. 19, § 20-20.080Montana
Yes
Healthcare providers or facilities
Laboratories
Other: Dentist; medical examiner; public or private school administrator; local health officer
All cases
Mont. Admin. R. 37.114.201;
Mont. Admin. R. 37.114.203;
Mont. Admin. R. 37.114.204Nebraska
Yes
Healthcare providers or facilities
Laboratories
All cases
173 Neb. Admin. Code § 1-004;
173 Neb. Admin. Code § 1-005Nevada
NoNew Hampshire
NoNew Jersey
NoNew Mexico
NoNew York
NoNorth Carolina
Yes
Laboratories
All cases
10A N.C. Admin. Code 41A.0101North Dakota
Yes
Healthcare providers or facilities
Laboratories
Other: Medical examiners or coroners; pharmacists; emergency medical service providers; local health officers; blood banks; public and private elementary and secondary schools; colleges and universities; correctional institutions; funeral establishments and mortuaries; childcare facilities and camps
All cases
N.D. Cent. Code § 23-07-02;
N.D. Admin. Code 33-06-01-01Ohio
NoOklahoma
NoOregon
NoPennsylvania
NoRhode Island
Yes
Healthcare providers or facilities
Laboratories
All cases
216 R.I. Code R. 30-05-1.4;
216 R.I. Code R. 30-05-1.5(.3)(E)(25);
216 R.I. Code R. 30-05-1.6;
216-RICR- 30-05-1.7South Carolina
Yes
Laboratories
Lab confirmed
S.C. Code Regs. 61-20; South Carolina 2021 List of Reportable ConditionsSouth Dakota
Yes
Healthcare providers or facilities
Laboratories
Other: Blood bank, collection or storage centers; public and private elementary and secondary schools; public and private universities and colleges; correctional institutions; funeral establishments and mortuaries; childcare facilities; food service, lodging and campground establishments
Other:  Latent infection in persons at higher risk
S.D. Admin. R. 44:20:02:01;
S.D. Admin. R. 44:20:02:02
S.D. Admin. R. 44:20:01:04Tennessee
Yes
Healthcare providers or facilities
Other:  Healthcare providers to report LTBI in child under 18 with positive tuberculin skin test (TST) or patient of any age with positive interferon-gamma release assay (IGRA) test
Tenn. Comp. R. & Regs. 1200-14-01-.02;
2021 Tennessee Reportable Disease List for Healthcare ProvidersTexas
Yes
Healthcare providers or facilities
Laboratories
Other: Local school authority; administrator or director of a child-care facility; administrator or director of adult care facility; administrator or health official of an institution of higher education; owner or manager of a food establishment; superintendent, manager, or health official of a camp, home or institution; administrator or health official of a penal or correctional institution; emergency medical service personnel, peace officer, or firefighter; a parent, guardian, or householder
All cases
Tex. Health & Safety Code § 81.042
25 Tex. Admin. Code § 97.2;
25 Tex. Admin. Code § 97.3Utah
NoVermont
Yes
Healthcare providers or facilities
Laboratories
All cases
12-5 Vt. Code R. 12:5.0Virginia
Yes
Healthcare providers or facilities
All cases
12 Va. Admin. Code § 5-90-80;
12 Va. Admin. Code § 5-90-90Washington
(state)
NoWashington, DC
NoWest Virginia
Yes
Healthcare providers or facilities
Laboratories
All cases
W. Va. Code St. R. § 64-7-3;
W. Va. Code St. R. § 64-76-7Wisconsin
Yes
Healthcare providers or facilities
Laboratories
Other: Any teacher, principal, or nurse serving a school or day care center; any person who knows or suspects that a person has a communicable disease
All cases
Wis. Stat. Ann. § 252.05;
Wis. Admin. Code Ch. DHS 145, App. A;
Wis. Admin. Code § DHS 145.04Wyoming
No1State websites included in this table were last visited 9/15/2022 and may differ from current webpages or PDFs. The current (2023) Georgia Notifiable Disease General Reporting Requirements can be found at NDCondition_5.12.23
2At the time of data collection, there was a discrepancy between New Hampshire’s Reportable Infectious Disease List , which listed “Tuberculosis infection, latent (lab reporting only)” as a reportable disease and New Hampshire regulations, which did not. S*ee* N.H. Code Admin R. He-P 301.02 (listing only “Tuberculosis Disease” and “Mycobacterium tuberculosis”).
3Current (2023) South Carolina List of Reportable Conditions is found at South Carolina List of Reportable Conditions | SCDHEC.  But see supra note 1.
4Current (2023) Tennessee Reportable Disease List for Healthcare Providers is found at 2023-Provider-list.pdf (tn.gov). But see supra note 1.Social Media Graphics, Web Button and InfographicsSocial Media GraphicsLTBI button 600x600

Download: JPG [600x600px]LTBI button 500x250

Download: JPG  [500x250px]
LTBI button 500x250

Download: JPG [500x250px]Web ButtonLTBI Button 200x200.jpg**Copy the code below to embed this image.(200×200)**InfographicsTake on Latent Tuberculosis (TB) InfectionTake on Latent Tuberculosis (TB) Infection [PDF – 240 KB]Tuberculosis (TB) Disease: Only the Tip of the IcebergTop of Page
							
					
							Last Reviewed:  May 1, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue